Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient's therapy course.

Daphne M V de Vries-HuizingMichelle W J VersleijenMichiel SinaasappelIris WalravenMartine M Geluk-JonkerMargot E T TesselaarJeroen J M A HendrikxBerlinda J de Wit-van der VeenMarcel P M Stokkel

Published in: PloS one (2021)

The incidence of severe haematotoxicity was low with extensive screening and monitoring. The vast majority of patients (96/100) was not restricted in treatment continuation by haematotoxicity; therefore, our selection criteria appeared appropriate for safe PRRT treatment. Baseline parameters showed limited correlation with the degree of decline in haematological values.

Keyphrases

end stage renal disease
newly diagnosed
risk factors
peritoneal dialysis
case report
early onset
cell therapy
bone marrow